Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia  Date: 2021-03-25

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07321332, are currently being conducted in the U.S.

The new drug pertains to the protease inhibitor class of antiviral drugs and can prevent viral replication in human cells, by blocking the production of an enzyme. For those unaware, protease inhibitors are commonly used for the treatment of viral pathogens like Hepatitis C and HIV.

Chief Scientific Officer of Pfizer, Mikael Dolsten reportedly said that both modes of prevention using vaccines and treatment for those affected with the virus are equally important to manage the coronavirus pandemic. The rapid mutation of SARS-CoV-2 along with the continued impact of the ongoing pandemic has necessitated access to curative measures in the long run.

The phase one trials for the oral antiviral drug are being performed in tandem with Pfizer’s development of PF-07304814, an intravenously administered protease inhibitor. The drug is currently in a phase 1 B clinical trial and is currently being tested on patients admitted in hospitals with COVID-19.

Even though drugmakers such as BioNTech and Pfizer have had their vaccines approved in the United States, analysts opine that the world will require a variety of drugs to arrest the pandemic.

Meanwhile, preclinical studies have exhibited that the oral drug, which is the first protease inhibitor to be analyzed in clinical trials, has a strong antiviral capacity against the virus, according to the firm.

The drug may be recommended to individuals who are newly infected with the virus as it can be ingested orally. Researchers hope that the drug will slow the progression of the disease and keep people out of the hospital.

Pfizer divulged that it would provide more information on the drug’s progress on 6th April 2021 at the American Chemical Society Spring Meeting.

Source Credit –

https://www.news18.com/news/world/pfizer-starts-early-stage-clinical-trial-testing-of-oral-antiviral-drug-for-coronavirus-report-3566318.html

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...